Multiple resistance mechanisms to azole antifungals in yeast clinical isolates

Drug Resistance Updates

Volumn 1, Issue 4, 1998, Pages 255-265

  Sanglard, Dominique ^a   Ischer, Françoise ^a   Calabrese, David ^a   Micheli, Michelle de ^a   Bille, Jacques ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001639420     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80006-X     Document Type: Review

References (80)

1. Beck-Sague C.M., and Jarwis W.R. NNISS. Secular trends in the empidiemology of nosocomial fungal infections in the United States. J Infect Dis 167 (1993) 1247-1251
2. Nguyen M.H., Peacock J.E., Morris A.J., et al. The changing face of candidemia - emergence of non-Candida albicans species and antifungal resistance. Am J Med 100 (1996) 617-623
3. Troillet N., Durussel C., Bille J., et al. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 12 (1993) 911-915
4. Ruhnke M., Eigler A., Engelmann E., et al. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 22 (1994) 132-136
5. Redding S., Smith J., Farinacci G., et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS - documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 18 (1994) 240-242
6. Georgopapadakou N.H., and Walsh T.J. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 40 (1996) 279-291
7. Vanden Bossche H., Marichal P., and Odds F.C. Molecular mechanisms of drug resistance in fungi. Trends Microbiol 2 (1994) 393-400
8. Odds F.C. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother 31 (1993) 463-471
9. Marichal P., and Vanden Bossche H. Mechanisms of resistance to azole antifungals. Acta Biochim Pol 42 (1995) 509-516
10. Odds F.C. Resistance of clinically important yeasts to antifungal agents. Int J Antimicrob Agents 6 (1996) 145-147
11. Vanden Bossche H. Chemotherapy of human fungal infections. In: Lyr H. (Ed). Modern selective fungicides. Properties, applications, mechanisms of action (1995), Gustav Fischer Verlag, Jena 431-484
12. Nelson D.R., Koymans I., Kamataki T., et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6 (1996) 1-42
13. Vanden Bossche H., Marichal P., and Moereels H. Molecular mechanisms of antifungal activity and fungal resistance: focus on inhibitors of ergosterol biosynthesis. In: Maresca B., Kobayashi G.S., and Yamaguchi H. (Eds). Molecular Biology and its Application to Medical Mycology (1993), Springer-Verlag, Berlin 179-197
14. Lyman C.A., and Walsh T.J. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44 (1992) 9-35
15. Kelly S.L., Lamb D.C., Baldwin B.C., Corran A.J., and Kelly D.E. Characterization of Saccharomyces cerevisiae CYP61, sterol delta22-desaturase, and inhibition by azole antifungal agents. J Biol Chem 272 (1997) 9986-9988
16. Vanden Bossche H., Marichal P., Le Jeune L., Coene M.C., et al. Effects of itraconazole on cytochrome P-450-dependent sterol 14α-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob Agents Chemother 37 (1993) 2101-2105
17. Vanden Bossche H., Marichal P., Gorrens J., et al. Mode of action of antifungals of use in immunocompromised patients. Focus on Candida glabrata and Histoplasma capsulatum. In: Vanden Bossche H., Mackenzie D.W.R., Cauwenbergh G., et al. (Eds). Mycoses in AIDS patients (1990), Plenum Press, New York 223-243
18. Holt R.J., and Azmi A. Miconazole-resistant Candida. Lancet 1 (1978) 50-51
19. Horsburgh C.R., and Kirkpatrick C.H. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med 74 Suppl. 1B (1983) 23-29
20. Johnson E.M., Richardson M.D., and Warnock D.W. In vitro resistance with imidazole antifungals in Candida albicans. J Antimicrob Chemother 13 (1984) 541-558
21. Vanden Bossche H., Warnock D.W., Dupont B., et al. Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol 32 S1 (1994) 189-202
22. Sanglard D., Kuchler K., Ischer F., et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39 (1995) 2378-2386
23. Calvet H.M., Yeaman M.R., and Filler S.G. Reversible fluconazole resistance in Candida albicans a potential in vitro model. Antimicrob Agents Chemother 41 (1997) 535-539
24. Rex J.H., Nelson P.W., Paetznick V.L., et al. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 42 (1998) 129-134
25. Drake J.W., Charlesworth B., Charlesworth D., and Crow J.F. Rates of spontaneous mutation. Genetics 148 (1998) 1667-1686
26. Ryloy J.F., Wilson G., and Barrett Bee K.J. Azole resistance in Candida albicans. J Med Vet Mycol 22 (1984) 53-63
27. Hitchcock C.A., Barrett B.K., and Russell N.J. The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. J Gen Microbiol 132 (1986) 2421-2431
28. Venkateswarlu K., Denning D.W., Manning N.J., and Kelly S.L. Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol Lett 131 (1995) 337-341
29. Hitchcock C.A., Pye G.W., Troke P.F., et al. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 37 (1993) 1962-1965
30. Parkinson T., Falconer D.J., and Hitchcock C.A. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 39 (1995) 1696-1699
31. Venkateswarlu K., Denning D.W., Manning N.J., and Kelly S.L. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother 40 (1996) 2443-2446
32. Venkateswarlu K., Taylor M., Manning N.J., et al. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 41 (1997) 748-751
33. Lees N.D., Broughton M.M., Sanglard D., and Bard M. Azole suceptibility and hyphal formation in a cytochrome P450-deficient mutant of Candida albicans. Antimicrob Agents Chemother 34 (1990) 831-836
34. Jensenpergakes K.L., Kennedy M.A., Lees N.D., et al. Sequencing, disruption, and characterization of the Candida albicans sterol methyltransferase (ERG6) gene - drug susceptibility studies in erg6 mutants. Antimicrob Agents Chemother 42 (1998) 1160-1167
35. Albertson G.D., Niimi M., Cannon R.D., and Jenkinson H.F. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 40 (1996) 2835-2841
36. Sanglard D., Ischer F., Monod M., and Bille J. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 40 (1996) 2300-2305
37. Sanglard D., Ischer F., Monod M., and Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC-transporter gene. Microbiol 143 (1997) 405-416
38. Balan I., Alarco A.M., and Raymond M. The Candida albicans CDR3 gene codes for an opaque-phase ABC transporter. J Bacteriol 179 (1997) 7210-7218
39. Walsh T.J., Kasar M., Francesconi A., et al. New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes - implications for antifungal azole resistance. J Med Vet Mycol 35 (1997) 133-137
40. Sullivan D.J., Westemeng T.J., Haynes K.A., et al. Candida dubliniensis sp nov - phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiol 141 (1995) 1507-1521
41. Moran G.P., Sullivan D.J., Henman M.C., et al. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother 41 (1997) 617-623
42. Moran G.P., Sanglard D., Donnelly S., et al. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother 42 (1998) 1819-1830
43. Krishnamurthy S., Gupta V., Snehlata P., and Prasad R. Characterisation of human steroid hormone transport mediated by Cdrlp, a multidrug transporter of Candida albicans, belonging to the ATP binding cassette super family. FEMS Microbiol Lett 158 (1998) 69-74
44. Balzi E., and Goffeau A. Genetics and biochemistry of yeast multidrug resistance. Biochim Biophys Acta 1187 (1994) 152-162
45. Miyahara K., Hirata D., and Miyakawa T. yAP-1- and yAP-2-mediated, heat shock-induced transcriptional activation of the multidrug resistance ABC transporter genes in Saccharomyces cerevisiae. Curr Genet 29 (1996) 103-105
46. Wemmie J.A., Szczypka M.S., Thiele D.J., and Moye R.W. Cadmium tolerance mediated by the yeast AP-I protein requires the presence of an ATP-binding cassette transporter-encoding gene, YCF I. J Biol Chem 269 (1994) 32592-32597
47. Alarco A.M., Balan I., Talibi D., et al. API-mediated multidrug resistance in Saccharomyces cerevisiae requires FLRI encoding a transporter of the major facilitator superfamily. J Biol Chem 272 (1997) 19304-19313
48. Hernaez M.L., Gil C., Pla J., and Nombela C. Induced expression of the Candida albicans multidrug resistance gene CDRI in response to fluconazole and other antifungals. Yeast 14 (1998) 517-526
49. Krishnamurthy S., Gupta V., Prasad R., et al. Expression of CDRI, a multidrug resistance gene of Candida albicans - transcriptional activation by heat shock, drugs and human steroid hormones. FEMS Microbiol Lett 160 (1998) 191-197
50. Vanden Bossche H., Marichal P., Gorrens J., et al. Mutation in cytochrome P450-dependent 14α-demethylase results in decreased affinity for azole antifungals. Biochem Soc Trans 18 (1990) 56-59
51. Lamb D.C., Corran A., Baldwin B.C., et al. Resistant P450AI activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. FEBS Lett 368 (1995) 326-330
52. Sanglard D., Ischer F., Koymans L., and Bille J. Amino acid substitutions in the cytochrome P450 lanosterol 14α-demethylase (CYP51AI) from azole-resistant Candida albicans clinical isolates contributing to the resistance to azole antifungal agents. Antimicrob Agents Chemother 42 (1998) 241-253
53. Loeffler J., Kelly S.L., Hebart H., et al. Molecular analysis of CYP51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett 151 (1997) 263-268
54. White T.C. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14-alpha-demethylase in Candida albicans. Antimicrob Agents Chemother 41 (1997) 1488-1494
55. White T.C. Increased mRNA levels of ERG16, CDR, and MDRI correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41 (1997) 1482-1487
56. Marichal P., Vanden Bossche H., Odds F.C., et al. Molecular-biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 41 (1997) 2229-2237
57. Kelly S.L., Lamb D.C., Kelly D.E., et al. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348 (1996) 1523-1524
58. Nolte F.S., Parkinson T., Falconer D.J., et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 44 (1997) 196-199
59. Geber A., Hitchcock C.A., Swartz J.E., et al. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother 39 (1995) 2708-2717
60. Kelly S.L., Lamb D.C., Corran A.J., et al. Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8,24(28) dien-38,6α-diol. Biochem Biophys Res Commun 207 (1995) 910-915
61. Bard M., Lees N.D., Turi T., et al. Sterol synthesis and viability of ERG11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans. Lipids 28 (1993) 963-967
62. Warson P.F., Rose V.E., and Reny S.L. Isolation and analysis of reconazole resistant mutants of Saccharomyces cerevisiae. J Med Vet Mycol 26 (1988) 153-162
63. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338 (1998) 853-860
64. Smith K.J., Warnock D.W., Kennedy C.T., et al. Azole resistance in Candida albicans. J Med Vet Mycol 24 (1986) 133-144
65. George D., Miniter P., and Andriole V.T. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 40 (1996) 86-91
66. Barchiesi F., Colombo A.L., Mcgough D.A., et al. In vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 38 (1994) 2553-2556
67. Wardle H.M., Law D., Moore C.B., et al. In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. Antimicrob Agents Chemother 39 (1995) 868-871
68. Galgiani J.N., and Lewis M.L. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother 41 (1997) 180-183
69. Hata K., Kimura J., Miki H., et al. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 40 (1996) 2237-2242
70. Clemons K.V., and Stevens D.A. Efficacies of two novel azole derivatives each containing a morpholone ring. UR-9746 and UR-9751, against systemic murine coccidioidomycosis. Antimicrob Agents Chemother 41 (1997) 200-203
71. Fung-Tomc J.C., Minassian B., Huezko E., et al. In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob Agents Chemother 39 (1995) 295-300
72. Bouffard F.A., Dropinski J.F., Balkovec J.M., et al. L-743,872, a novel antifungal lipopeptide: synthesis and structure-activity relationships of new aza-substituted pneumocandins. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 15-18, 1996 (1996)
73. Stevens D.A., Martinez M., and Devine M.J. Antifungal activity of LY303366 (LY), an echinocandin beta glucan synthase inhibitor (GSI). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 15-18, 1996 (1996)
74. Debono M., and Gordee R.S. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 48 (1994) 471-497
75. Mazur P., Morin N., Baginsky W., et al. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol 15 (1995) 5671-5681
76. Douglas C.M., Marrinan J.A., Li W., and Kurtz M.B. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase. J Bacteriol 176 (1994) 5686-5696
77. Kurtz M.B., Abruzzo G., Bartizal K., et al. Characterization of echinocandin resistant mutants of Candida albicans- genetic, biochemical, and virulence studies. Infect Immun 64 (1996) 3244-3251
78. Kellen J.A. Multidrug resistance. In: Kellen J.A. (Ed). Reversal of multidrug resistance in cancer (1994), CRC Press, Boca Raton FL 1-19
79. Beck W.T. Modulators of P-glycoprotein-associated multidrug resistance. In: Ozols R.F. (Ed). Molecular and Clinical Advances in Anticancer Drug Resistance (1991), Kluwer Academic Publ., Boston 151-170
80. Egner K., Rosenthal F.E., Kralli A., et al. Genetic separation of FK506 susceptibility and drug transport in the yeast Pdr5 ATP-binding Cassette multidrug resistance transporter. Mol Biol Cell 9 (1998) 523-543